NCT06382519View on ClinicalTrials.gov

Thalidomide Therapy for VEOIBD

RecruitingOBSERVATIONAL

Enrollment

40

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Inflammatory Bowel Diseases

Interventions

DRUG

Thalidomide

thalidomide, dose 1.5-2.5mg/kg.d, orally taken before bedtime.

Trial Locations (1)

201102

RECRUITING

Lin Wang, Shanghai

All Listed Sponsors

lead

Children's Hospital of Fudan University

OTHER